Survey finds one third of RA patients hide extent of symptoms

14 October 2007

New research highlighting the devastating impact of rheumatoid arthritis on peoples' lives has found that one third of people with RA do not always tell their health care professionals the true extent of their symptoms. When asked why, 19% of respondents to a recent poll conducted by ICM confessed that they were worried about having their treatment taken away and one in four admitted that they were worried that there might not be any other treatment options available.

Andrew Ostor, consultant rheumatologist at Addenbrooke's Hospital, Cambridge, UK, said: "these findings make for worrying reading. We know the key to effective disease management is open and honest communication between patients and their clinician and these results suggest this isn't happening, leaving patients in unnecessary pain. There are a variety of treatments available, including recently-approved therapies such as rituximab which targets the B-cells in the inflammatory cascade. It should be within the grasp of all people with RA to have their disease effectively managed." Sue Oliver, a UK nurse consultant in rheumatology, added: "we need to make sure we are encouraging patients to talk openly about their symptoms."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight